Evidence map›Paper›PMID 36945366›Full record

ArticlebioRxiv : the preprint server for biology2023

Targeted Phasing of 2-200 Kilobase DNA Fragments with a Short-Read Sequencer and a Single-Tube Linked-Read Library Method.

Veronika Mikhaylova, Madison Rzepka, Tetsuya Kawamura, Yu Xia, Peter L Chang, Shiguo Zhou, Long Pham, Naisarg Modi, Likun Yao, Adrian Perez-Agustin and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Veronika MikhaylovaUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Madison RzepkaUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Tetsuya KawamuraUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Yu XiaUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Peter L ChangUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Shiguo ZhouSage Science Inc., Beverly, MA 01915, USA.
Long PhamUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Naisarg ModiUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Likun YaoDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093 USA.
Adrian Perez-AgustinDepartment of Medical Sciences, School of Medicine, University of Girona, Girona, Spain.
Sara PagansDepartment of Medical Sciences, School of Medicine, University of Girona, Girona, Spain.
T Christian BolesSage Science Inc., Beverly, MA 01915, USA.
Ming LeiUniversal Sequencing Technology Corp., Canton, MA 02021, USA.
Yong WangUniversal Sequencing Technology Corp., Canton, MA 02021, USA.
Ivan Garcia-BassetsUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Zhoutao ChenUniversal Sequencing Technology Corp., Carlsbad, CA 92011, USA.
Universal Technical Institute · USSage Science (United States) · USUniversitat de Girona · ESUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the human genome, heterozygous sites are genomic positions with different alleles inherited from each parent. On average, there is a heterozygous site every 1-2 kilobases (kb). Resolving whether two alleles in neighboring heterozygous positions are physically linked-that is, phased-is possible with a short-read sequencer if the sequencing library captures long-range information. TELL-Seq is a library preparation method based on millions of barcoded micro-sized beads that enables instrument-free phasing of a whole human genome in a single PCR tube. TELL-Seq incorporates a unique molecular identifier (barcode) to the short reads generated from the same high-molecular-weight (HMW) DNA fragment (known as 'linked-reads'). However, genome-scale TELL-Seq is not cost-effective for applications focusing on a single locus or a few loci. Here, we present an optimized TELL-Seq protocol that enables the cost-effective phasing of enriched loci (targets) of varying sizes, purity levels, and heterozygosity. Targeted TELL-Seq maximizes linked-read efficiency and library yield while minimizing input requirements, fragment collisions on microbeads, and sequencing burden. To validate the targeted protocol, we phased seven 180-200 kb loci enriched by CRISPR/Cas9-mediated excision coupled with pulse-field electrophoresis, four 20 kb loci enriched by CRISPR/Cas9-mediated protection from exonuclease digestion, and six 2-13 kb loci amplified by PCR. The selected targets have clinical and research relevance (

Identifiers

PMID36945366
PMCPMC10028795
OpenAlexW4323663028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.